| LVRNA009 / AIM Vaccine |
NCT05428592: Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad |
|
|
| Not yet recruiting | 3 | 1100 | RoW | LVRNA009, CoronaVac® | AIM Vaccine Co., Ltd. | SARS-CoV-2 | 10/23 | 10/24 | | |
NCT05682638: A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 |
|
|
| Recruiting | 3 | 34000 | RoW | LVRNA009, 0.9%NaCl | AIM Vaccine Co., Ltd., AIM Innovation Biotechnology (Shanghai) Co., Ltd, Ningbo Rongan Biological Pharmaceutical Co. Ltd., LiveRNA Therapeutics Inc. | SARS-CoV-2 | 12/24 | 12/25 | | |
NCT05352867: Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People |
|
|
| Completed | 2 | 420 | RoW | SARS-CoV-2 (LVRNA009) 50μg group, SARS-CoV-2 (LVRNA009) 100μg group, Placebo | AIM Vaccine Co., Ltd., Hunan Provincial Center for Disease Control and Prevention | SARS-CoV-2 | 06/22 | 06/23 | | |
ChiCTR2200057782: A Phase II clinical trial to evaluate the immunogenicity and safety of novel coronavirus mRNA vaccine (LVRNA009) in a Chinese population aged 18-59 years |
|
|
| Recruiting | 2 | 420 | | 1 dose of 50 μg test vaccine was administered intramuscularly on days 0 and 28 respectively ;1 dose of 100 μg test vaccine was administered intramuscularly on days 0 and 28 respectively ;placebo | Hu'nan Provincial Center for Disease Control and Prevention; Zhuhai Liverna Therapeutics Inc, self-funded | Novel Coronavirus Pneumonia (COVID-19) | | | | |
NCT05364047: Clinical Trial of SARS-CoV-2 mRNA Vaccine in China |
|
|
| Active, not recruiting | 1 | 144 | RoW | Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009, Placebo | AIM Vaccine Co., Ltd., Shulan (Hangzhou) Hospital, Yuncheng Central Hospital | COVID-19 | 10/22 | 10/23 | | |
| Not yet recruiting | 1 | 144 | | Investigational vaccine or placebo of corresponding dose ;Investigational vaccine or placebo of corresponding dose ;Investigational vaccine or placebo of corresponding dose ;Investigational vaccine or placebo of corresponding dose ;Investigational vaccine or placebo of corresponding dose ;Investigational vaccine or placebo of corresponding dose | Shulan (Hangzhou) Hospital; Zhuhai Liverna Therapeutics Inc, Self-financed | Novel Coronavirus Pneumonia (COVID-19) | | | | |
